Bibliographic record
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a…
Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I. The Lancet 2021
§1Bibliographic record
§1.1Record
- Authors
- Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I
- Title
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- Source
- The Lancet
- Year
- 2021
- Volume, issue, pages
- 397(10278):971–984
- Digital object identifier
- 10.1016/S0140-6736(21)00213-0
- PubMed identifier
- 33667417
- Record type
- Journal article
- Institute identifier
- CEI-BR-014
§1.2Institute documents citing this record
Table 1. Documents in the Institute set that cite this record.
§1.3Subject tags
semaglutide obesity t2dm STEP
Compound Evidence Institute · CEI-BR-014 · https://compoundevidence.com/bibliography/davies2021/ · retrieved 30 July 2026